Armodafinil ( DrugBank: Armodafinil )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
| 84 | Sarcoidosis | 1 |
6. Parkinson disease
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01256905 (ClinicalTrials.gov) | January 1, 2011 | 8/12/2010 | Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies | Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies | Parkinsons Disease;Lewy Bodies Disease | Drug: Armodafinil | NYU Langone Health | Cephalon | Withdrawn | 50 Years | 80 Years | All | 0 | N/A | United States |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00981084 (ClinicalTrials.gov) | September 2009 | 18/9/2009 | Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS) | The Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis: a Double-Blind Randomized Crossover Study | Multiple Sclerosis | Drug: armodafinil | University of Missouri, Kansas City | University of Kansas | Completed | 18 Years | 60 Years | All | 33 | Phase 2/Phase 3 | United States |
84. Sarcoidosis
Clinical trials : 149 / Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00555347 (ClinicalTrials.gov) | October 2007 | 7/11/2007 | Use of Armodafinil for Fatigue in Sarcoidosis | Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis | Sarcoidosis;Fatigue;Sleepiness | Drug: Armodafinil;Drug: Placebo | University of Cincinnati | Cephalon | Completed | 18 Years | N/A | Both | 20 | Phase 2/Phase 3 | United States |